Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming infected with HIV. But big questions remain over the drug’s affordability.

The Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that has been shown to act as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. The drug,